Integra LifeSciences forecasts 2026 adjusted EPS of $2.30-$2.40

• Integra LifeSciences updated its 2026 revenue outlook to $1.63 billion-$1.65 billion, reflecting Cincinnati flood disruption and softer Tissue Reconstruction growth.
• Full-year adjusted earnings guidance stands at $2.30-$2.40 per share, with organic revenue growth of -0.3% to 0.9%.
• Fourth-quarter revenue is projected at $413 million-$433 million, with adjusted earnings of $0.61-$0.71 per share.
• Cincinnati flood disruption is expected to reduce quarterly revenue by $15 million-$20 million, primarily affecting Neurosurgery.
• Full-year adjusted gross margins and adjusted EBITDA are expected to remain flat versus 2025, reflecting unfavorable mix and Cincinnati impacts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.